Clinical Trials
59 trialsNCT04739800 2026-04-13
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT02817958 2025-06-26
MEGACEP
UNICANCER
Phase 2 Active not recruiting
NCT06415318 2025-04-22
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02033993 2023-08-22
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003518 2023-06-22
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00005644 2023-06-22
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00077129 2023-06-18
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003614 2023-06-15
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00432094 2022-05-17
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04221828 2022-03-29
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Phase 2 Terminated
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00005028 2019-11-04
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT03077659 2019-08-20
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
NanOlogy, LLC
Phase 2 Completed
NCT02109328 2019-04-11
Alisertib in Chemotherapy-pretreated Urothelial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00467051 2018-08-29
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT00310011 2018-08-10
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
Wake Forest University Health Sciences
Phase 2 Completed
NCT00268450 2018-07-12
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 2 Terminated
NCT00055601 2018-06-15
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00470366 2017-11-28
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00531687 2017-10-03
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
Rigshospitalet, Denmark
Phase 2 Terminated
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT00183820 2017-07-07
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
University of Southern California
Phase 2 Completed
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01558492 2017-06-09
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00002931 2017-02-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00683059 2016-10-17
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00022633 2016-08-11
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
SWOG Cancer Research Network
Phase 2 Terminated
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003852 2016-06-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
UNICANCER
Phase 2 Terminated
NCT00933374 2015-03-18
RAD001
Heinrich-Heine University, Duesseldorf
Phase 2 Terminated
NCT00136175 2015-01-21
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00151034 2015-01-21
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00151060 2015-01-21
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00003717 2013-12-19
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004077 2013-12-19
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00028769 2013-07-16
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00028860 2013-07-10
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084565 2013-07-10
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00002684 2013-07-03
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00045630 2013-05-27
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
SWOG Cancer Research Network
Phase 2 Completed